177 related articles for article (PubMed ID: 34817046)
21. CD45RO
Zhou WJ; Zhang J; Xie F; Wu JN; Ye JF; Wang J; Wu K; Li MQ
Theranostics; 2021; 11(11):5330-5345. PubMed ID: 33859750
[No Abstract] [Full Text] [Related]
22. PPP1R14B is a diagnostic prognostic marker in patients with uterine corpus endometrial carcinoma.
He K; Wang T; Huang X; Yang Z; Wang Z; Zhang S; Sui X; Jiang J; Zhao L
J Cell Mol Med; 2023 Mar; 27(6):846-863. PubMed ID: 36824011
[TBL] [Abstract][Full Text] [Related]
23. ALDH2 promotes uterine corpus endometrial carcinoma proliferation and construction of clinical survival prognostic model.
Cui YQ; Xiang Y; Meng F; Ji CH; Xiao R; Li JP; Dai ZT; Liao XH
Aging (Albany NY); 2021 Oct; 13(20):23588-23602. PubMed ID: 34670872
[TBL] [Abstract][Full Text] [Related]
24. Bioinformatics reveal elevated levels of Myosin Vb in uterine corpus endometrial carcinoma patients which correlates to increased cell metabolism and poor prognosis.
Engevik KA; Engevik MA; Engevik AC
PLoS One; 2023; 18(1):e0280428. PubMed ID: 36662766
[TBL] [Abstract][Full Text] [Related]
25. Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D.
Timmerman S; Van Rompuy AS; Van Gorp T; Vanden Bempt I; Brems H; Van Nieuwenhuysen E; Han SN; Neven P; Victoor J; Laenen A; Vergote I
Gynecol Oncol; 2020 Apr; 157(1):245-251. PubMed ID: 31980219
[TBL] [Abstract][Full Text] [Related]
26. Lack of association between deficient mismatch repair expression and outcome in endometrial carcinomas of the endometrioid type.
Ruiz I; MartÃn-Arruti M; Lopez-Lopez E; Garcia-Orad A
Gynecol Oncol; 2014 Jul; 134(1):20-3. PubMed ID: 24814467
[TBL] [Abstract][Full Text] [Related]
27. Construction of prediction model for prognosis of uterine corpus endometrial carcinoma based on pyroptosis gene.
Zhang C; Bai J; Yang Y; Wang X; Liu W; Hou S; Ai Z; Xia Q; Shao L
Clin Transl Oncol; 2023 May; 25(5):1413-1424. PubMed ID: 36520385
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological role of Cyclin A2 in uterine corpus endometrial carcinoma: Integration of tissue microarrays and ScRNA-Seq.
Mo WJ; Liang ZQ; Huang JZ; Huang ZG; Zhi ZF; Chen JH; Chen G; Zeng JJ; Feng ZB
Int J Biol Markers; 2024 Jun; 39(2):168-183. PubMed ID: 38646803
[TBL] [Abstract][Full Text] [Related]
29. Sporadic endometrial adenocarcinoma with MMR deficiency due to biallelic MSH2 somatic mutations.
Buecher B; De Pauw A; Bazire L; Houdayer C; Fievet A; Moncoutier V; Farkhondeh F; Melaabi S; Lyonnet DS; Golmard L
Fam Cancer; 2018 Apr; 17(2):281-285. PubMed ID: 28819700
[TBL] [Abstract][Full Text] [Related]
30. m
Fang F; Wang P; Huang H; Ye M; Liu X; Li Q
BMC Cancer; 2022 Dec; 22(1):1364. PubMed ID: 36581816
[TBL] [Abstract][Full Text] [Related]
31. A comprehensive analysis and experimental validation of TK1 in uterine corpus endometrial carcinoma.
Sun Y; Zhang K; Wang T; Zhao S; Gao C; Xue F; Wang Y
Sci Rep; 2024 Mar; 14(1):6134. PubMed ID: 38480789
[TBL] [Abstract][Full Text] [Related]
32. [Dysregulation of MAD2L1/CAMK2A/PTTG1 Gene Cluster Maintains the Stemness Characteristics of Uterine Corpus Endometrial Carcinoma].
Zheng J; Zhang YW; Pan ZF
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2021 Oct; 43(5):685-695. PubMed ID: 34728029
[TBL] [Abstract][Full Text] [Related]
33. The utility of evaluating mismatch repair proteins in endometrial carcinoma: an experience from a tertiary referral centre in North India.
Jain E; Prasad S; Dhar A; Kini L; Sharma S; Dewan A
Pathologica; 2021 Apr; 113(2):115-120. PubMed ID: 34042092
[TBL] [Abstract][Full Text] [Related]
34. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors.
Salem ME; Bodor JN; Puccini A; Xiu J; Goldberg RM; Grothey A; Korn WM; Shields AF; Worrilow WM; Kim ES; Lenz HJ; Marshall JL; Hall MJ
Int J Cancer; 2020 Nov; 147(10):2948-2956. PubMed ID: 32449172
[TBL] [Abstract][Full Text] [Related]
35. The Identification of Gamma-Glutamyl Hydrolase in Uterine Corpus Endometrial Carcinoma: a Predictive Model and Machine Learning.
Zhu C; Du Y; Huai Q; Fang N; Xu W; Yang J; Li X; Zhang Y; Zhang X; Dai H; Li X; Wang H; Dai Y
Reprod Sci; 2024 Feb; 31(2):532-549. PubMed ID: 37798609
[TBL] [Abstract][Full Text] [Related]
36. UBE2C serves as a prognosis biomarker of uterine corpus endometrial carcinoma via promoting tumor migration and invasion.
Ma S; Chen Q; Li X; Fu J; Zhao L
Sci Rep; 2023 Oct; 13(1):16899. PubMed ID: 37803076
[TBL] [Abstract][Full Text] [Related]
37. Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer.
Mills AM; Liou S; Ford JM; Berek JS; Pai RK; Longacre TA
Am J Surg Pathol; 2014 Nov; 38(11):1501-9. PubMed ID: 25229768
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathological features of 50 mismatch repair (MMR)-deficient endometrial carcinomas, tested by immunohistochemistry: A single institutional feasibility study, India.
Rekhi B; Menon S; Deodhar KK; Ghosh J; Chopra S; Maheshwari A
Ann Diagn Pathol; 2020 Aug; 47():151558. PubMed ID: 32619922
[TBL] [Abstract][Full Text] [Related]
39. MMP11 and MMP17 are potential biomarkers for uterine corpus endometrial carcinoma prognosis.
Zhang Y; Wang J; Fan Y; Lang F; Fu F; Liu Q
Clin Transl Oncol; 2024 Mar; 26(3):653-663. PubMed ID: 37523078
[TBL] [Abstract][Full Text] [Related]
40. Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities.
Garg K; Leitao MM; Kauff ND; Hansen J; Kosarin K; Shia J; Soslow RA
Am J Surg Pathol; 2009 Jun; 33(6):925-33. PubMed ID: 19238076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
